Morgan Stanley Call 450 MDGL 20.1.../ DE000MG0D896 /
6/5/2024 5:56:50 PM | Chg.- | Bid9:54:44 AM | Ask9:54:44 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.530EUR | - | 0.500 Bid Size: 1,000 |
0.580 Ask Size: 1,000 |
Madrigal Pharmaceuti... | 450.00 USD | 12/20/2024 | Call |
GlobeNewswire
6/5
Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conferenc...
GlobeNewswire
5/29
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes R...
GlobeNewswire
5/7
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire
4/23
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, ...
GlobeNewswire
4/16
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
4/9
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of...
GlobeNewswire
4/5
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for ...
GlobeNewswire
4/3
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
3/19
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
GlobeNewswire
3/14
FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population
GlobeNewswire
3/14
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Pati...
GlobeNewswire
3/6
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
3/5
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Res...
GlobeNewswire
2/28
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Fi...
GlobeNewswire
2/21
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2/8
Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in th...
GlobeNewswire
2/6
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)